Core Viewpoint - Yifan Pharmaceutical Co., Ltd. reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, indicating strong operational performance and growth in innovative drug sales [2][6]. Financial Performance - The company's operating income for the reporting period was approximately CNY 2.635 billion, a year-on-year increase of 0.11% [2][6]. - Net profit attributable to shareholders reached approximately CNY 303.65 million, reflecting a year-on-year growth of 19.91% [2][6]. - The net profit after deducting non-recurring gains and losses was approximately CNY 237.21 million, up 32.21% year-on-year [6][10]. - Basic earnings per share increased to CNY 0.25, a rise of 19.05% compared to the previous year [2][3]. Business Highlights - Revenue from pharmaceutical-related operations was approximately CNY 2.254 billion, accounting for 85.53% of total revenue, with innovative drugs Yilishu and Yinikang showing a combined sales increase of 169.57% [6][10]. - The company successfully launched its first self-developed Class I macromolecule innovative biological drug, Yilishu, in the U.S. market, with a terminal price of USD 4,600 per unit [7][10]. - Yilishu has been approved for sale in 34 countries/regions and has achieved sales in five countries, with ongoing regulatory applications in Thailand, the Philippines, Malaysia, and the UAE [7][9]. Strategic Developments - The company established a global business development center to enhance international market expansion and collaboration [11][12]. - Yifan Pharmaceutical is focusing on the commercialization of Yilishu and optimizing costs, with significant partnerships established across over 40 countries [7][10]. - The company is advancing its research and development efforts, with several new drug applications submitted and clinical trials approved for various products [13][14]. Market Position - The company’s overseas pharmaceutical formulations generated revenue of approximately CNY 331.99 million, a year-on-year increase of 6.46% [10][11]. - Domestic pharmaceutical sales reached approximately CNY 1.921 billion, reflecting a growth of 3.57% year-on-year, driven by product matrix optimization and marketing strategy upgrades [10][11].

Core Viewpoint - Yifan Pharmaceutical Co., Ltd. reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, driven by innovative drug sales and operational efficiency improvements [2][3][12]. Company Overview - Yifan Pharmaceutical is a publicly listed company on the Shenzhen Stock Exchange, specializing in the research, development, production, and sales of pharmaceutical products, including biological drugs, chemical drugs, and traditional Chinese medicine [2][3]. - The company has a strong international presence, with products approved for sale in over 50 countries, including China, the USA, the EU, and Brazil [8][9]. Financial Performance - The company achieved operating revenue of approximately CNY 2.635 billion in the first half of 2025, a 0.11% increase year-on-year [3][12]. - Net profit attributable to shareholders was CNY 237.21 million, reflecting a 32.21% increase compared to the previous year [3][12]. - The basic earnings per share rose to CNY 0.25, a 19.05% increase from the previous period [3][12]. Business Segments - The main business activities include the development and sales of pharmaceutical products, vitamins, and high polymer materials [3][12]. - The company’s innovative drug, Yili Shu (艾贝格司亭 α), has been successfully commercialized in multiple international markets, marking a significant milestone for the company [13][14]. Market Position - Yifan Pharmaceutical holds a leading position in the vitamin B5 market, with over 70% of its sales directed towards international markets, particularly in Europe and North America [6][9]. - The company is recognized for its unique products, including those listed in the World Health Organization's essential medicines list, and has a robust pipeline of innovative drugs [8][11]. Industry Context - The pharmaceutical industry in China is undergoing significant transformation, with a shift towards innovative drugs amid pressures on traditional generic markets [6][7]. - The vitamin industry is experiencing structural changes, with increased competition and a focus on technological advancements to enhance product offerings [6][7]. Strategic Initiatives - The company is actively pursuing global expansion strategies, focusing on brand development and channel integration to enhance its market presence [17][18]. - Ongoing projects include the development of new drug candidates and the establishment of international research and production facilities to support its growth objectives [16][17].

Core Points - The company held its 18th meeting of the 8th Board of Directors, where all 8 directors participated and approved several key resolutions [1][2][3] Meeting Details - The meeting was convened in accordance with the Company Law and the Articles of Association, ensuring compliance with relevant regulations [1] - All resolutions were passed with unanimous support, with 8 votes in favor and no votes against or abstentions [2][3] Financial Reports - The Board approved the 2025 Half-Year Report and its summary, which will be disclosed on the company's official information platform [1] Board Elections - The Board approved the nomination of candidates for the 9th Board of Directors, including non-independent directors and independent directors, with all candidates receiving unanimous support [2][3] Amendments to Company Regulations - Several amendments to the company's internal regulations were approved, including revisions to the Articles of Association, Shareholders' Meeting Rules, and Board Meeting Rules [4][5][6] - The company also approved changes to the Independent Director Work System and the Management of Raised Funds [5][6] Independent Director Compensation - The Board approved an increase in the compensation for independent directors from RMB 100,000 to RMB 150,000 per year, reflecting the company's operational context and market conditions [6][7] Upcoming Shareholder Meeting - The Board resolved to convene the second extraordinary general meeting of shareholders in 2025 to discuss the approved resolutions [8]

证券代码：002019 证券简称：亿帆医药 公告编号：2025-045 亿帆医药股份有限公司 第八届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 经审核，监事会认为：公司董事会编制和审核《2025 年半年度报告》和《2025 年半年度报告摘要》的程序符合法律、行政法规和中国证监会的规定，报告内容 真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述 或者重大遗漏。 三、备查文件 亿帆医药股份有限公司监事会 《第八届监事会第十五次会议决议》 一、监事会会议召开情况 亿帆医药股份有限公司（以下简称"公司"）第八届监事会第十五次会议于 公司一楼会议室召开。会议由监事会主席许国汉先生主持，会议应参加表决的监 事 3 人，实际参加表决的监事 3 人。会议的召开符合《公司法》和《公司章程》 的相关规定，会议合法有效。 二、监事会会议审议情况 特此公告。 经全体监事认真审议，会议以投票表决的方式形成以下决议： （一）会议以 3 票同意、0 票反对、0 票弃权的结果，审议通过了《公司 2025 年半年度报告及其摘要》 ...

Financial Overview - The total assets of Yifan Pharmaceutical Co., Ltd. increased from CNY 12,285,788,088.75 at the beginning of the period to CNY 12,674,139,895.70 at the end, representing a growth of approximately 3.17% [1][2] - Total liabilities rose from CNY 3,858,992,750.77 to CNY 4,017,412,350.66, indicating an increase of about 4.1% [2][3] - The total equity increased from CNY 8,426,795,337.98 to CNY 8,656,727,545.04, reflecting a growth of approximately 2.72% [2][3] Income Statement Highlights - The total operating revenue for the first half of 2025 was CNY 2,635,110,083.18, slightly up from CNY 2,632,089,783.35 in the same period of 2024 [3][4] - Total operating costs decreased from CNY 2,363,162,281.95 to CNY 2,316,453,207.97, showing a reduction of about 1.98% [4] - Net profit for the first half of 2025 was CNY 284,158,135.82, compared to CNY 212,445,979.23 in the first half of 2024, marking an increase of approximately 33.8% [4][5] Cash Flow Analysis - Net cash flow from operating activities improved significantly, rising from CNY 143,774,218.95 in the first half of 2024 to CNY 286,097,071.23 in the first half of 2025 [5] - Cash flow from investing activities showed a net outflow of CNY 159,041,410.09, compared to a larger outflow of CNY 195,466,241.92 in the previous year [5] - Cash flow from financing activities resulted in a net outflow of CNY 147,413,242.53, contrasting with a net inflow of CNY 207,793,148.58 in the first half of 2024 [5] Balance Sheet Insights - Current assets totaled CNY 3,967,724,843.29 at the end of the period, up from CNY 3,778,271,166.02 at the beginning, indicating a growth of approximately 5.03% [1][2] - Non-current assets increased from CNY 8,507,516,922.73 to CNY 8,706,415,052.41, reflecting a growth of about 2.34% [1][2] - The company's cash and cash equivalents decreased from CNY 889,388,507.75 to CNY 785,909,109.30, a decline of approximately 11.6% [1][2]

Meeting Announcement - Yifan Pharmaceutical Co., Ltd. will hold its second extraordinary general meeting of shareholders for 2025 on September 5, 2025 [1][2] - The meeting will start at 1:30 PM and will include both on-site and online voting options [1][2] Voting Procedures - Shareholders can vote either in person or through the Shenzhen Stock Exchange trading system and internet voting system, but must choose one method [2][5] - The online voting will be available from 9:15 AM to 11:30 AM and from 1:00 PM to 3:00 PM on the same day [1][2] Eligibility and Registration - All ordinary shareholders registered by the close of business on August 29, 2025, are eligible to attend and vote [2][4] - Registration can be done via on-site, mail, or fax before August 29, 2025 [4] Agenda Items - The meeting will include proposals that require a two-thirds majority vote from attending shareholders for special resolutions [3][4] - Proposals include amendments to the company's articles of association and the election of directors [3][4] Contact Information - For inquiries, shareholders can contact Feng Dexi or Li Lei at the provided phone numbers and email [4]

证券代码：002019 证券简称：亿帆医药 公告编号：2025-047 亿帆医药股份有限公司 独立董事候选人声明与承诺 声明人曾玉红作为亿帆医药股份有限公司第九届董事会独立董事候选人， 已充分了解并同意由提名人亿帆医药股份有限公司董事会提名为亿帆医药股 份有限公司（以下简称"该公司"）第九届董事会独立董事候选人。现公开声 明和保证，本人与该公司之间不存在任何影响本人独立性的关系，且符合相关 法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董 事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 如否，请详细说明： 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所 业务规则规定的独立董事任职资格和条件。 ? 是 □否 如否，请详细说明： ? 是 □否 如否，请详细说明： 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担任 公司董事的情形。 四、本人符合该公司章程规定的独立董事任职条件。 ? 是 □否 ? 是 □否 一、本人已经通过亿帆医药股份有限公司第九届董事会提名委员会或者独 立董事专门会议资格审查，提名人与本人不存在利害关系或者其他可能影响独 立履职情 ...

亿帆医药股份有限公司 | | 编制单位：亿帆医药股份有限公司 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 单位：万元 | | | | | | | | | | | | | | | | 占用方与上市公 | 上市公司核算 | 2025 年期初占用 | | 计 | 2025 年 | 1-6 月占用 | 2025 年 | 1-6 月偿 | | 还 2025 年 | 6 月 | 30 | | | | | | | | | | | | 非经营性资金占用 | | 资金占用方名 | | | | | | | | | | 称 | | | | | | | | | 占用形成原因 | 占用性质 | | | | | | 司的关联关系 | 的会计科目 | 资金余额 | | 发生金额（不含利 | | 资金的利息(如有) | | 累计发 | | 生金额 | 日占用资金余额 | | | | | | | | | | | | | | | | | | 息） | | | | | | | | 控股股东、实际控 ...

证券代码：002019 证券简称：亿帆医药 公告编号：2025-048 亿帆医药股份有限公司 独立董事候选人声明与承诺 声明人刘梅娟作为亿帆医药股份有限公司第九届董事会独立董事候选人， 已充分了解并同意由提名人亿帆医药股份有限公司董事会提名为亿帆医药股 份有限公司（以下简称"该公司"）第九届董事会独立董事候选人。现公开声 明和保证，本人与该公司之间不存在任何影响本人独立性的关系，且符合相关 法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董 事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 如否，请详细说明： 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担任 公司董事的情形。 ? 是 □否 一、本人已经通过亿帆医药股份有限公司第九届董事会提名委员会或者独 立董事专门会议资格审查，提名人与本人不存在利害关系或者其他可能影响独 立履职情形的密切关系。 ? 是 □否 如否，请详细说明： 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所 业务规则规定的独立董事任职资格和条件。 ? 是 □否 如否，请详细说明： 四、本人符合该公司章程规定的独立董事任职条件。 ...

Core Viewpoint - The company is revising its Articles of Association to align with updated legal regulations and its operational realities, which will be submitted for shareholder approval [1]. Summary by Sections Company Structure and Governance - The company is established as a joint-stock limited company in accordance with the Company Law and other relevant regulations [2]. - The legal representative of the company will be the president, who is elected by the board of directors [3]. Amendments to Articles of Association - The first article has been amended to include employees alongside shareholders and creditors in protecting their legal rights [1]. - New provisions have been added to clarify the responsibilities of the legal representative and the company's liability for civil activities conducted in its name [4]. Shareholder Rights and Responsibilities - Shareholders are entitled to rights based on their shareholdings, including profit distribution and participation in decision-making processes [12]. - Shareholders holding more than 5% of shares must report any pledging of their shares to the company [39]. Capital Structure and Share Issuance - The total number of shares issued by the company is 1,216,390,085, all of which are ordinary shares [7]. - The company can increase its capital through various methods, including public offerings and private placements, subject to shareholder approval [8]. Share Repurchase and Financial Assistance - The company may repurchase its shares through public trading or other legally recognized methods, with specific conditions outlined for different scenarios [9][10]. - Financial assistance for acquiring shares is limited to 10% of the total issued capital [7]. Shareholder Meetings and Decision-Making - The company’s shareholder meetings are the highest authority, responsible for major decisions such as approving financial reports and capital changes [21]. - Specific conditions are set for convening extraordinary shareholder meetings, including significant losses or requests from major shareholders [23]. Compliance and Legal Obligations - The company and its controlling shareholders must adhere to legal obligations and maintain transparency in operations, including timely disclosure of significant events [19][20].